Immunotherapy-related Adverse Events in Real-world Patients with Advanced Non-small Cell Lung Cancer on Chemoimmunotherapy: a Spinnaker Study Sub-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jun 16

PMID 37324003

Authors

Shobana Anpalakhan

Prerana Huddar

Roya Behrouzi

Alessio Signori

Judith Cave

Charles Comins

Alessio Cortellini

Alfredo Addeo

Carles Escriu

Hayley McKenzie

Gloria Barone

Lisa Murray

David J Pinato

Christian Ottensmeier

Sara Campos

Sethupathi Muthuramalingam

Samuel Chan

Fabio Gomes

Giuseppe L Banna

Affiliations

Soon will be listed here.

Abstract

Background: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse effects (irAEs) seen in this cohort, their impact on overall survival (OS) and progression-free survival (PFS), and related clinical factors.

Methods: The Spinnaker study was a retrospective multicentre observational cohort study of patients treated with first-line pembrolizumab plus platinum-based chemotherapy in six United Kingdom and one Swiss oncology centres. Data were collected on patient characteristics, survival outcomes, frequency and severity of irAEs, and peripheral immune-inflammatory blood markers, including the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII).

Results: A total of 308 patients were included; 132 (43%) experienced any grade irAE, 100 (32%) Grade 1-2, and 49 (16%) Grade 3-4 irAEs. The median OS in patients with any grade irAES was significantly longer (17.5 months [95% CI, 13.4-21.6 months]) than those without (10.1 months [95% CI, 8.3-12.0 months]) (p<0.001), either if Grade 1-2 (p=0.003) or Grade 3-4 irAEs (p=0.042). The median PFS in patients with any grade irAEs was significantly longer (10.1 months [95% CI, 9.0-11.2 months]) than those without (6.1 months [95% CI, 5.2-7.1 months]) (p<0.001), either if Grade 1-2 (p=0.011) or Grade 3-4 irAEs (p=0.036). A higher rate of irAEs of any grade and specifically Grade 1-2 irAEs correlated with NLR <4 (p=0.013 and p=0.018), SII <1,440 (p=0.029 ad p=0.039), response to treatment (p=0.001 and p=0.034), a higher rate of treatment discontinuation (p<0.00001 and p=0.041), and the NHS-Lung prognostic classes (p=0.002 and p=0.008).

Conclusions: These results confirm survival outcome benefits in patients with irAEs and suggest a higher likelihood of Grade 1-2 irAEs in patients with lower NLR or SII values or according to the NHS-Lung score.

Citing Articles

Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy.

Du Y, Zhang Y, Zhao W, Zhang Y, Su F, Zhang X Hum Vaccin Immunother. 2024; 20(1):2398309.

PMID: 39267589 PMC: 11404634. DOI: 10.1080/21645515.2024.2398309.

Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study.

Gao Y, Li H, Qiu L, Yuan H, Fan Q, Niu Z Sci Prog. 2024; 107(3):368504241272703.

PMID: 39166262 PMC: 11339938. DOI: 10.1177/00368504241272703.

Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials.

Yu A, Fu F, Li X, Wu M, Yu M, Zhang W Front Oncol. 2024; 14:1351359.

PMID: 38454928 PMC: 10917905. DOI: 10.3389/fonc.2024.1351359.

References

Liu W, Liu Y, Ma F, Sun B, Wang Y, Luo J . Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Manag Res. 2021; 13:765-771. PMC: 7850423. DOI: 10.2147/CMAR.S293200. View

Banna G, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A . Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. Int Immunopharmacol. 2022; 110:108985. DOI: 10.1016/j.intimp.2022.108985. View

Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S . Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. J Immunother. 2019; 43(1):1-7. DOI: 10.1097/CJI.0000000000000300. View

Banna G, Friedlaender A, Tagliamento M, Mollica V, Cortellini A, Rebuzzi S . Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer. Curr Oncol Rep. 2022; 24(12):1851-1862. DOI: 10.1007/s11912-022-01335-8. View

Zer A, Sung M, Walia P, Khoja L, Maganti M, Labbe C . Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018; 19(5):426-434.e1. DOI: 10.1016/j.cllc.2018.04.008. View

Takeda T, Takeuchi M, Saitoh M, Takeda S . Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. Thorac Cancer. 2018; 9(10):1291-1299. PMC: 6166075. DOI: 10.1111/1759-7714.12838. View

Pistillo M, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R . Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunol Immunother. 2018; 68(1):97-107. PMC: 11028053. DOI: 10.1007/s00262-018-2258-1. View

Suh K, Kim S, Kim Y, Kim M, Keam B, Kim T . Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. 2017; 67(3):459-470. PMC: 11028357. DOI: 10.1007/s00262-017-2092-x. View

Cheung Y, Wang W, McGregor B, Hamnvik O . Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022; 71(8):1795-1812. PMC: 9276851. DOI: 10.1007/s00262-021-03128-7. View

10.

Hara M, Nagasaki T, Shiga K, Takahashi H, Takeyama H . High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab. Surg Today. 2016; 47(4):483-489. DOI: 10.1007/s00595-016-1404-7. View

11.

Socinski M, Jotte R, Cappuzzo F, Nishio M, Mok T, Reck M . Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol. 2023; 9(4):527-535. PMC: 9936386. DOI: 10.1001/jamaoncol.2022.7711. View

12.

Fujimoto A, Toyokawa G, Koutake Y, Kimura S, Kawamata Y, Fukuishi K . Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 2021; 12(15):2198-2204. PMC: 8327687. DOI: 10.1111/1759-7714.14063. View

13.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

14.

Nigro O, Pinotti G, De Galitiis F, Di Pietro F, Giusti R, Filetti M . Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. Eur J Cancer. 2020; 134:19-28. DOI: 10.1016/j.ejca.2020.04.025. View

15.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

16.

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

17.

Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C . The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. Int J Mol Sci. 2023; 24(2). PMC: 9867035. DOI: 10.3390/ijms24021746. View

18.

Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H . Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol. 2021; 11:703893. PMC: 8277237. DOI: 10.3389/fonc.2021.703893. View

19.

Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y . The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. Lung Cancer. 2019; 130:159-161. DOI: 10.1016/j.lungcan.2019.02.011. View

20.

Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N . Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer. 2018; 20(3):201-207. DOI: 10.1016/j.cllc.2018.10.002. View